000282954 001__ 282954
000282954 005__ 20251218155009.0
000282954 0247_ $$2doi$$a10.1212/NXI.0000000000200520
000282954 0247_ $$2pmid$$apmid:41406408
000282954 037__ $$aDZNE-2025-01415
000282954 041__ $$aEnglish
000282954 082__ $$a610
000282954 1001_ $$00000-0003-4991-4287$$aWetzel, Nora Sandrine$$b0
000282954 245__ $$aPatient-Derived Monoclonal Myelin Oligodendrocyte Glycoprotein Autoantibodies Mediate Cytotoxicity.
000282954 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2026
000282954 3367_ $$2DRIVER$$aarticle
000282954 3367_ $$2DataCite$$aOutput Types/Journal article
000282954 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766069300_31259
000282954 3367_ $$2BibTeX$$aARTICLE
000282954 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282954 3367_ $$00$$2EndNote$$aJournal Article
000282954 520__ $$aSerum myelin oligodendrocyte glycoprotein (MOG) antibodies are a hallmark of the newly defined neuroinflammatory disease entity MOG antibody-associated disease (MOGAD). Yet, the lack of patient-derived recombinant human MOG (hMOG)-reactive autoantibodies limits investigations into the molecular mechanisms by which these autoantibodies mediate CNS pathology, thereby hindering rational therapeutic approaches. To understand the origins and disease-relevant mechanisms of autoantibodies in MOGAD, we generated and characterized monoclonal anti-hMOG antibodies (MOG-mAbs) from circulating B cells of patients with MOGAD.We isolated MOG-specific B-cell receptor (BCR) sequences from unique circulating B-cell clones of 6 patients with MOGAD using an antigen selection approach. BCR sequences were expressed as immunoglobulin (Ig)G1 antibodies, and their molecular features, epitope specificity, and binding to MOG isoforms were investigated. The MOG-mAbs' ability to mediate antibody-dependent cellular phagocytosis (ADCP), natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC) toward MOG-expressing cells was assessed by live cell-based assays.Of the 15 MOG-mAbs generated, 4 revealed evidence of affinity maturation, whereas the remaining 11 were germline encoded. Binding capacities to hMOG varied considerably, with the most frequent putative epitope mapping to a region that includes residue P42. The efficacy of these antibodies in mediating ADCP, ADCC, and CDC of MOG-expressing cells was heterogeneous and associated with their binding characteristics to MOG and its isoforms.Taken together, the molecular characteristics and binding patterns of these patient-derived MOG-mAbs reveal a diverse repertoire of MOG-binding autoantibodies with pathogenic capacity in vitro. Consequently, these well-characterized patient autoantibodies offer a foundation for developing in vivo models of MOGAD, serve as tools to standardize diagnostic assays, and guide development of therapeutic strategies targeting either B cells or autoantibodies and their effector functions.
000282954 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282954 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282954 650_7 $$2NLM Chemicals$$aMyelin-Oligodendrocyte Glycoprotein
000282954 650_7 $$2NLM Chemicals$$aAutoantibodies
000282954 650_7 $$2NLM Chemicals$$aMOG protein, human
000282954 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal
000282954 650_2 $$2MeSH$$aHumans
000282954 650_2 $$2MeSH$$aMyelin-Oligodendrocyte Glycoprotein: immunology
000282954 650_2 $$2MeSH$$aAutoantibodies: immunology
000282954 650_2 $$2MeSH$$aAntibodies, Monoclonal: immunology
000282954 650_2 $$2MeSH$$aFemale
000282954 650_2 $$2MeSH$$aMale
000282954 650_2 $$2MeSH$$aAdult
000282954 650_2 $$2MeSH$$aMiddle Aged
000282954 650_2 $$2MeSH$$aB-Lymphocytes: immunology
000282954 650_2 $$2MeSH$$aAntibody-Dependent Cell Cytotoxicity: immunology
000282954 7001_ $$00000-0001-5236-8323$$aKulsvehagen, Laila$$b1
000282954 7001_ $$00009-0003-4174-4049$$aLecourt, Anne-Catherine$$b2
000282954 7001_ $$00000-0003-4166-5650$$aFilipek, Beata$$b3
000282954 7001_ $$00009-0002-5910-7622$$aLipps, Patrick$$b4
000282954 7001_ $$aRieder, Laura$$b5
000282954 7001_ $$aBerve, Kristina$$b6
000282954 7001_ $$0P:(DE-HGF)0$$aKrishnamoorthy, Gurumoorthy$$b7
000282954 7001_ $$a't Hart, Bert A$$b8
000282954 7001_ $$00000-0001-7142-4116$$aSchirmer, Lucas$$b9
000282954 7001_ $$aYandamuri, Soumya S$$b10
000282954 7001_ $$aO'Connor, Kevin C$$b11
000282954 7001_ $$0P:(DE-2719)9003515$$aPröbstel, Anne-Katrin$$b12$$eLast author
000282954 773__ $$0PERI:(DE-600)2767740-0$$a10.1212/NXI.0000000000200520$$gVol. 13, no. 1, p. e200520$$n1$$pe200520$$tNeurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology$$v13$$x2332-7812$$y2026
000282954 8564_ $$uhttps://pub.dzne.de/record/282954/files/DZNE-2025-01415.pdf$$yRestricted
000282954 8564_ $$uhttps://pub.dzne.de/record/282954/files/DZNE-2025-01415.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282954 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000282954 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003515$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000282954 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282954 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROL-NEUROIMMUNOL : 2022$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-13T18:57:06Z
000282954 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-13T18:57:06Z
000282954 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-02-13T18:57:06Z
000282954 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROL-NEUROIMMUNOL : 2022$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-27
000282954 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-27
000282954 9201_ $$0I:(DE-2719)1013045$$kAG Pröbstel$$lClinical Neurology and Neuroimmunology$$x0
000282954 980__ $$ajournal
000282954 980__ $$aEDITORS
000282954 980__ $$aVDBINPRINT
000282954 980__ $$aI:(DE-2719)1013045
000282954 980__ $$aUNRESTRICTED